We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > antibody-drug conjugate

News List

Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer b3cnewswire
July 28, 2020
Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first patients have started treatment in its Phase II study evaluating the safety and efficacy of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarma
ImmunoGen's antibody-drug conjugate mirvetuximab soravtansine misses main goal of Phase III ovarian cancer study firstwordpharma
March 03, 2019
ImmunoGen announced Friday that a Phase III study of the experimental antibody-drug conjugate (ADC) mirvetuximab soravtansine in patients with folate receptor (FR) alpha-positive, platinum-resistant ovarian cancer failed to meet its primary endpoint of pr